ConcertAI Provides Intelligent Automation of ASCO ® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ ® SmartLinQ™ Solutions
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite's low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes.
In December of 2023, ASCO and ConcertAI announced the acquisition of CancerLinQ and ongoing network operations as a ConcertAI initiative. Over the last year and a half, ConcertAI has advanced the SmartLinQ application for QOPI® applications as well as advanced notifications of potentially beneficial diagnostics and newly approved therapeutics for a provider's patients. SmartLinQ works directly within the workflows of Epic and other EMRs. ASCO Guidelines will be augmenting the SmartLinQ solution by June 15th as part of the company's effort to assure that all network practices have that informational resource.
On May 30 th, ConcertAI announced its oncology Precision Suite™ of generative and agentic AI solutions for advancing analytics and inferences, and for clinical trial design and optimization. The ASCO Guidelines will be available within these solutions by June 30 th for assessment of Guideline-concordant care across the widest array of settings, and to inform the design of clinical trial controls according to published clinical recommendations.
'Through CancerLinQ, ConcertAI has an almost decade-long history of collaborating with ASCO,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This license of ASCO Guidelines represents a new opportunity to harness the latest generative and agentic AI technologies to promote high-quality cancer care, evidence generation, and advanced care insights.'
The CancerLinQ SmartLinQ deployment of these guidelines will be available to demonstrate at the 2025 ASCO Annual Meeting in Chicago.
About ConcertAI:
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Renesas Announces Expected Loss Resulting from Signing Restructuring Support Agreement with Wolfspeed
TOKYO--(BUSINESS WIRE)--Renesas Electronics Corporation (TSE: 6723, "Renesas"), a premier supplier of advanced semiconductor solutions, today announced that it has entered into a Restructuring Support Agreement (the "Restructuring Support Agreement") with Wolfspeed, Inc. (NYSE: WOLF, "Wolfspeed") and its principal creditors for the financial restructuring of Wolfspeed. As a result, Renesas expects to record a loss as described below. 1. Details of Loss As , Renesas entered into the silicon carbide wafer supply agreement with Wolfspeed, and through Renesas' wholly owned subsidiary in the United States, it provided a deposit (the "Deposit") of US$2 billion (approximately 292.0 billion yen) to Wolfspeed. In October 2024, Renesas and Wolfspeed amended their agreement and increased the outstanding principal amount of the Deposit to US$2.062 billion (approximately 301.1 billion yen). Subsequently, Wolfspeed has experienced financial challenges. On May 8, 2025, during its quarterly earnings call, Wolfspeed disclosed that to achieve its stated goal of strengthening its balance sheet, it may implement a transaction through an in-court solution. Due to Wolfspeed's contemplation of an in-court option, Wolfspeed included required going concern language in the footnotes to its financial statements for the quarterly period ended March 30, 2025. In response to this situation, Renesas has been engaging in discussions with Wolfspeed and today entered into the Restructuring Support Agreement among Wolfspeed and its principal creditors, pursuant to which Renesas agreed to, among other things, convert the Deposit of US$2.062 billion into convertible notes, common stock, and warrants issued by Wolfspeed as follows (the 'Restructuring'). Wolfspeed convertible notes: US$204 million (approximately 29.8 billion yen) in aggregate principal amount, convertible to Wolfspeed common stock, maturing in June 2031. These notes are convertible into 13.6% of Wolfspeed's total issued shares on a non-diluted basis at the time of the completion of the Restructuring. On a fully diluted basis, and prior to the exercise of the warrants to be granted to Renesas, this corresponds to 11.8%. Wolfspeed common stock: equivalent to 38.7% (17.9% on a fully diluted basis, prior to Renesas warrants exercise) of the total number of issued shares of Wolfspeed at the completion of the Restructuring. Wolfspeed warrants: equivalent to 5% (on a fully diluted basis) of the total number of issued shares of Wolfspeed at the completion of the Restructuring. The Restructuring is expected to be consummated through proceedings under Chapter 11 of the U.S. Bankruptcy Code. It is expected that Wolfspeed will file a petition with the court to initiate such proceedings in the near future. The Restructuring is expected to become effective by the end of September 2025, subject to court approval of the restructuring plan. If the necessary regulatory approvals have not been obtained by the time the Restructuring takes effect, Renesas will hold rights to instruments with equivalent economic value to Wolfspeed's convertible notes, common stock, and warrants until those approvals are received. In connection with the signing of the Restructuring Support Agreement, Renesas expects to record a loss on the deposited receivables related to the Deposit in its consolidated financial statements. Although the timing and amount of such loss have not been determined at this time, Renesas believes that there is a possibility of recording a loss of approximately 250 billion yen (converted at an average exchange rate of 150 yen to the dollar during the period) in the consolidated financial statements for the six months ending June 30, 2025. Please note that this amount is an estimate calculated by Renesas' internal analysis based on the currently available information and may increase or decrease due to various factors. The definitive timing and amount of the loss to be recorded will be determined in consultation with Renesas' auditor and will be announced once it is determined. 2. Future Outlook Renesas discloses revenue, gross margin, and operating margin on a "Non-GAAP" basis and does not disclose a forecast for profit attributable to owners of parent. Therefore, there is no change to the forecast for the six months ending June 30, 2025, announced on April 24, 2025. (Note1) Unless otherwise indicated, yen equivalents in this material are calculated using the exchange rate as of June 20, 2025: 146 yen to the dollar. (Note2) Non-GAAP figures are calculated by removing or adjusting non-recurring items and other adjustments from GAAP (IFRS basis) figures following a certain set of rules. Renesas believes non-GAAP measures provide useful information in understanding and evaluating its constant business results, and therefore, forecasts are provided on a non-GAAP basis. This adjustment and exclusion include the amortization of intangible assets recognized from acquisitions, other PPA (purchase price allocation) adjustments and stock-based compensation, as well as other non-recurring expenses and income Renesas believes to be applicable. Expand About Renesas Electronics Corporation Renesas Electronics Corporation (TSE: 6723) empowers a safer, smarter and more sustainable future where technology helps make our lives easier. A leading global provider of microcontrollers, Renesas combines our expertise in embedded processing, analog, power and connectivity to deliver complete semiconductor solutions. These Winning Combinations accelerate time to market for automotive, industrial, infrastructure and IoT applications, enabling billions of connected, intelligent devices that enhance the way people work and live. Learn more at Follow us on LinkedIn, Facebook, Twitter, YouTube, and Instagram. (FORWARD-LOOKING STATEMENTS) The statements in this press release with respect to the plans, strategies and financial outlook of Renesas and its consolidated subsidiaries (collectively 'we') are forward-looking statements involving risks and uncertainties. Such forward-looking statements do not represent any guarantee by management of future performance. In many cases, but not all, we use such words as 'aim,' 'anticipate,' 'believe,' 'continue,' 'endeavor,' 'estimate,' 'expect,' 'initiative,' 'intend,' 'may,' 'plan,' 'potential,' 'probability,' 'project,' 'risk,' 'seek,' 'should,' 'strive,' 'target,' 'will' and similar expressions to identify forward-looking statements. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These statements discuss future expectations, identify strategies, contain projections of our results of operations or financial condition, or state other forward-looking information based on our current expectations, assumptions, estimates and projections about our business and industry, our future business strategies and the environment in which we will operate in the future. Known and unknown risks, uncertainties and other factors could cause our actual results, performance or achievements to differ materially from those contained or implied in any forward-looking statement, including, but not limited to, general economic conditions in our markets, which are primarily Japan, North America, Asia, and Europe; demand for, and competitive pricing pressure on, products and services in the marketplace; ability to continue to win acceptance of products and services in these highly competitive markets; fluctuations in currency exchange rates, particularly between the yen and the U.S. dollar; and risks and uncertainties associated with Wolfspeed's proceedings under Chapter 11 of the U.S. Bankruptcy Code, including Wolfspeed's ability to maintain relationships with suppliers, customers, employees and other third parties and regulatory authorities as a result of such proceedings, and other factors discussed in Wolfspeed's filings with the U.S. Securities and Exchange Commission. Among other factors, a downturn of the world economy; deteriorating financial conditions in world markets, or a deterioration in domestic and overseas stock markets, may cause actual results to differ from the projected results forecast. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. This press release is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither we nor our advisors or representatives are under an obligation to update, revise, or affirm.
Business Wire
an hour ago
- Business Wire
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
BOSTON--(BUSINESS WIRE)-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. "Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not and speed is critical' said Brad Murray, chief executive officer of Delve Bio. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. 'This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup,' said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. 'This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections.' The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? 'These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical,' said Brad Murray, chief executive officer of Delve Bio. 'We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need.' Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit
Business Wire
2 hours ago
- Business Wire
Shift4 to Acquire Australian Payments Leader Smartpay
CENTER VALLEY, Pa. & AUCKLAND, New Zealand--(BUSINESS WIRE)-- Shift4 (NYSE: FOUR), a leader in integrated payments and commerce technology, has announced it has signed a definitive agreement to acquire Smartpay (NZX:SPY, ASX:SMP), a leading independent provider of payment processing and point-of-sale solutions in Australia and New Zealand, for NZ$296.4 million (~$180m USD), or NZ$1.20 per share. This represents a 46.5% premium to 90 trading day Volume Weighted Average Price (VWAP). Smartpay sells tailored payment solutions through an extensive distribution network across Australia and New Zealand, supporting a diverse base of more than 40,000 merchants in the region. The acquisition is expected to close in the fourth quarter of 2025, subject to regulatory approvals. 'This acquisition follows the Shift4 playbook to a tee. It deepens our strategic presence in Australia and New Zealand, providing a significant opportunity to offer our full suite of software and payments solutions in the region,' said Shift4 CEO Taylor Lauber. 'By combining our payment infrastructure with Smartpay's distribution capabilities, we're well positioned to go-to-market at scale in the region with our leading products and services such as SkyTab POS for restaurants, SkyTab Venue for stadiums and arenas, and our end-to-end payment solution for hotels and unified commerce merchants.' Shift4 has successfully executed a similar strategy of combining acquisitions to deliver a superior integrated payment experience with localized distribution, service, and support, valuable merchant-facing products, and owned payment rails to rapidly scale in other regions, most recently in Germany, the UK and Ireland. About Shift4 Shift4 (NYSE: FOUR) is boldly redefining commerce by simplifying complex payments ecosystems across the world. As the leader in commerce-enabling technology, Shift4 powers billions of transactions annually for hundreds of thousands of businesses in virtually every industry. For more information, visit About Smartpay Smartpay (NZX:SPY, ASX:SMP) is the leading independent provider of electronic funds transfer at point of sale (EFTPOS) solutions in Australia and New Zealand. Smartpay designs, develops and implements point-of-sale payment solutions for more than 40,000 merchants. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our expectations associated the completion, the benefits, synergies, efficiencies, and opportunities arising from, and anticipated costs of the proposed transaction, and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause each of our actual results, performance or achievements, to be materially different from any futures results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the substantial and increasingly intense competition worldwide in the financial services, payments and payment technology industries; our ability to continue to expand our respective share of the existing payment processing markets or expand into new markets; additional risks associated with our expansion into international operations, including compliance with and changes in foreign governmental policies, as well as exposure to foreign exchange rates; regulatory approvals and other related issues; and our respective ability to integrate and interoperate each of our services and products with a variety of operating systems, software, devices, and web browsers, and the other important factors discussed under the caption 'Risk Factors' in Part I, Item 1A in Shift4's Annual Report on Form 10-K for the years ended December 31, 2024, as updated by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and our other filings with the SEC. Any such forward-looking statements represent management's expectations as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause of our view to change.
